atoltivimab, maftivimab, and odesivimab-ebgn
| Brand name | Inmazeb |
|---|---|
| Active ingredient | atoltivimab, maftivimab, and odesivimab-ebgn |
| Strength | 483.3MG, 483.3MG, 483.3MG/14.5ML (33.33MG, 33.33MG, 33.33MG/ML) |
| Dosage form | Injection |
| Route | Intravenous |
| Modality | Biologic |
| FDA approval | September 2021 |
| Marketing status | Rx |
Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.